Ubiquitin Proteasome System as Target for Tumor TherapyMohamed Hassan 1,2,3*, Abdelouahid El-Khattouti 1, Youssef Haikel,2,3 and Mosaad Megahed4
- *Corresponding Author:
- Dr. Mohamed Hassan
University of Mississippi Medical Center
Jackson, MS 39216, USA
Tel.: +1 601 815 8945
Fax:+1 601 984 29 81
Received Date: November 9, 2014 Accepted Date: November 26, 2014 Published Date: December 9, 2014
Citation: Mohamed Hassan , Abdelouahid El-Khattouti, Youssef Haikel , Mosaad Megahed (2015) Ubiquitin Proteasome System as Target for Tumor Therapy. Chemo Open Access 4:142. doi: 10.4172/2167-7700.1000142
Copyright: ©2014 Hassan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Targeting the ubiquitin-proteasome pathway gained more attention as a rational approach in the treatment of human cancer. The 26S proteasome (2000-kDa) complex, which degrades ubiquitinated proteins, contains in addition to the 20S proteasome a 19S regulatory complex composed of multiple ATP ases and components necessary for binding protein substrates. Accordingly, proteasome is considered an exciting target for the development of anticancer therapies. Inhibition of proteasome machinery has shown a positive clinical benefit for cancer patients. Thus, the highlight of the mechanistic role of proteasome regulators, both inhibitors and activators, may help to improve the outcome of tumor treatment. In this review, we will focus on the molecular action of proteasome regulators in tumor treatment.